G1
G1 Therapeutics (Licella)
RTP NCFounded 2008100 employees
Private CapbiotechAcquiredOncology
Platform: Trilaciclib CDK
Market Cap
N/A
All Drugs
4
Clinical Trials
11
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Adagrainavolisib | G1-7753 | Phase 2/3 | 1 | FcRn | CRCADPKD | ||
| Ribomavacamten | G1-6778 | Phase 3 | 3 | EZH2 | MesoFabry | ||
| G1-8409 | G1-8409 | Phase 3 | 3 | Cl18.2 | DMDRCC | ||
| G1-2036 | G1-2036 | Phase 3 | 4 | Tau | LGS |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (10)